Medicamen Biotech Limited — Board Meeting, 13-02-2026: Outcome of Board Meeting
13-02-2026 | 04:06 pm
13-02-2026 | 04:06 pm
Medicamen Biotech's board approved Q3 & 9M consolidated financial results, with Q3 consolidated EPS at Rs. 1.21. Independent Directors Mr. Pande & Mr. Kumar completed their tenure. The board also reconstituted key committees.
No comments yet. Be the first to comment!
